VXX‐301, a muti‐epitope active immunotherapy targeting Tau, induces antibodies with favorable binding to Tau and exhibits efficacy in vivo
Justin Boyd, JC Dodart, Stefan Prokop · 2025
Read VXX‐301, a muti‐epitope active immunotherapy targeting Tau, induces antibodies with favorable binding to Tau and exhibits efficacy in vivo by Justin Boyd, JC Dodart, Stefan Prokop (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11712812.txt.
Description
Justin Boyd, JC Dodart, and Stefan Prokop report early tests of a vaccine aimed at the tau protein in Alzheimer's disease, in this 2025 paper. The vaccine, VXX-301, trains the immune system against two regions of tau, a protein whose clumping harms brain cells. Rats given the vaccine made strong antibody levels against both target regions.
The antibodies bound many forms of tau, including clumps, and also bound tau in human brain tissue samples. In dishes, they blocked cells from taking up tau and slowed its clumping. Mice bred to develop tau disease were shielded from movement problems and early death. The team plans further work toward human use.
Catalog record
| CREATOR | Justin Boyd, JC Dodart, Stefan Prokop |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |